Difference between revisions of "Angiosarcoma"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8})" to "[https://clinicaltrials.gov/ct2/show/$1 Clinical Trial Registry]") |
||
Line 36: | Line 36: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''NU 04S1:''' Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. Epub 2012 Aug 21. [https://doi.org/10.1093/annonc/mds237 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22910841/ PubMed] NCT00288015 | + | #'''NU 04S1:''' Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. Epub 2012 Aug 21. [https://doi.org/10.1093/annonc/mds237 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22910841/ PubMed] [https://clinicaltrials.gov/ct2/show/NCT00288015 Clinical Trial Registry] |
==Paclitaxel monotherapy {{#subobject:6e2606|Regimen=1}}== | ==Paclitaxel monotherapy {{#subobject:6e2606|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
Line 84: | Line 84: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | #'''TAPPAS:''' Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):740-747. [https://doi.org/10.1001/jamaoncol.2021.3547 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8972152/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35357396/ PubMed] NCT02979899 | + | #'''TAPPAS:''' Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):740-747. [https://doi.org/10.1001/jamaoncol.2021.3547 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8972152/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35357396/ PubMed] [https://clinicaltrials.gov/ct2/show/NCT02979899 Clinical Trial Registry] |
[[Category:Angiosarcoma regimens]] | [[Category:Angiosarcoma regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Vascular sarcomas]] | [[Category:Vascular sarcomas]] |
Revision as of 15:15, 31 May 2023
3 regimens on this page
3 variants on this page
|
Note: this page contains regimens specific to angiosarcoma.
Guidelines
ESMO
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) PubMed
NCCN
All lines of therapy
Bevacizumab monotherapy
Regimen
Study | Dates of enrollment | Evidence |
---|---|---|
Agulnik et al. 2012 (NU 04S1) | 2005-08 to 2011-04 | Phase 2 |
References
- NU 04S1: Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013 Jan;24(1):257-63. Epub 2012 Aug 21. link to original article contains dosing details in manuscript PubMed Clinical Trial Registry
Paclitaxel monotherapy
Regimen
Study | Evidence |
---|---|
Penel et al. 2008 (ANGIOTAX) | Phase 2 |
Chemotherapy
- Paclitaxel (Taxol) 80 mg/m2 IV over 60 minutes once per day on days 1, 8, 15
Supportive therapy
- Dexamethasone (Decadron) 8 mg IV once per day on days 1, 8, 15, prior to Paclitaxel (Taxol)
- Cimetidine (Tagamet) 200 mg IV once per day on days 1, 8, 15, prior to Paclitaxel (Taxol)
- Dexchlorpheniramine (Polaramine) 5 mg IV once per day on days 1, 8, 15, prior to Paclitaxel (Taxol)
- "Standard antiemetics (mainly Metoclopramide (Reglan)) were prescribed as clinically indicated by the treating physician"
28-day cycle for 6 cycles
References
- ANGIOTAX: Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008 Nov 10;26(32):5269-74. Epub 2008 Sep 22. link to original article contains dosing details in manuscript PubMed
Pazopanib monotherapy
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Jones et al. 2022 (TAPPAS) | 2017-2019 | Phase 3 (C) | Pazopanib & Carotuximab | Did not meet primary endpoint of PFS |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT in this context, prior to becoming a standard comparator arm.
References
- TAPPAS: Jones RL, Ravi V, Brohl AS, Chawla S, Ganjoo KN, Italiano A, Attia S, Burgess MA, Thornton K, Cranmer LD, Cheang MCU, Liu L, Robertson L, Adams B, Theuer C, Maki RG. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 May 1;8(5):740-747. link to original article link to PMC article PubMed Clinical Trial Registry